CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

Phase 3mosunetuzumabrituximab
Related Companies

Read the original article

Published by GlobeNewswire Pharma on September 17, 2026 5:00 AM

Read Original